Mackay Shields LLC’s Harvard Bioscience HBIO Stock Holding History

Mackay Shields LLC’s Portfolio HBIO Stock Details HBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-4,154	Closed	-$179K	–	1445
2019 Q1	$179K	Buy	4,154 +310	+8%	+$11.2K	﹤0.01%	1348
2018 Q4	$123K	Buy	3,844 +1,404	+58%	+$55.3K	﹤0.01%	1344
2018 Q3	$128K	Sell	2,440 -540	-18%	-$30.3K	﹤0.01%	1091
2018 Q2	$160K	Buy	+2,980	New	+$153K	﹤0.01%	1183

Other funds holding HBIO

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

ECM

Engine Capital Management New York $828M AUM 6.49% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DGHMC

Dalton, Greiner, Hartman, Maher & Co New York $126M AUM 92.88% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Mackay Shields LLC's HBIO Position: Q2 2019 in Review

Mackay Shields LLC sold out of Harvard Bioscience (HBIO) in Q2 2019, closing a stake of 4,154 shares — an estimated $179K sold.

Mackay Shields LLC first reported a position in HBIO in Q2 2018 and held it in 4 quarters. The position peaked at $179K in Q1 2019. 78 funds tracked by Wall St. Rank hold HBIO as of Q2 2019.

Mackay Shields LLC reported no remaining Harvard Bioscience position as of Q2 2019 after selling out during the quarter.
Mackay Shields LLC sold 4,154 Harvard Bioscience shares in Q2 2019, an estimated $179K.
Mackay Shields LLC first reported a position in Harvard Bioscience in Q2 2018 and held it in 4 quarters.
Mackay Shields LLC's Harvard Bioscience position peaked at $179K in Q1 2019.
78 funds tracked by Wall St. Rank held Harvard Bioscience as of Q2 2019.

Based on Mackay Shields LLC's 13F filing for Q2 2019, filed 13 Aug 2019.